ProMIS Neurosciences Inc. — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ProMIS reported blinded 6-month interim safety and biomarker data from PRECISE-AD, a Phase 1b trial of PMN310 in 136 mild cognitive impairment/mild AD patients (61% APOE4 carriers, 11% homozygotes). Key findings: zero ARIA-E cases across all genotypes, 4.4% total ARIA (all mild asymptomatic ARIA-H), zero treatment-related serious adverse events, zero drug discontinuations, and favorable biomarker trends (68.5% showed plasma pTau217 decline; 62.5% showed CSF MTBR-tau243 decline). Unblinded 12-month topline results expected Q1 2027.
Why this rating
Early Phase 1b safety/biomarker data in small clinical-stage company; no efficacy readout yet. Positive interim signals meaningful relative to $29.7M market cap and de-risking a lead candidate, but unblinded efficacy remains unknown; modest value erosion risk if 12-month data disappoints.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.